FDA inspection
Island Kinetics, Inc. d.b.a. CoValence Laboratories: FDA inspection ending Nov 12, 2004
FDA inspection 353721 · Voluntary Action Indicated (VAI) · Chandler, AZ
Key facts
| Inspection ID | 353721 |
|---|---|
| Firm | Island Kinetics, Inc. d.b.a. CoValence Laboratories |
| FEI number | 3002408934 |
| Address | 460 S Benson Ln Ste 1-3 |
| City | Chandler |
| State | AZ |
| ZIP | 85224-5663 |
| Fiscal year | 2005 |
| Inspection end date | Nov 12, 2004 |
| Classification | Voluntary Action Indicated (VAI) |
| Project area | Colors and Cosmetics Technology|Colors and Cosmetics Technology|Colors and Cosmetics Technology|Colors and Cosmetics Technology|Colors and Cosmetics Technology|Colors and Cosmetics Technology|Colors and Cosmetics Technology|Colors and Cosmetics Technology|Colors and Cosmetics Technology|Colors and Cosmetics Technology|Colors and Cosmetics Technology|Colors and Cosmetics Technology|Colors and Cosmetics Technology|Colors and Cosmetics Technology|Colors and Cosmetics Technology|Colors and Cosmetics Technology|Colors and Cosmetics Technology|Colors and Cosmetics Technology|Colors and Cosmetics Technology|Colors and Cosmetics Technology|Colors and Cosmetics Technology|Colors and Cosmetics Technology|Colors and Cosmetics Technology|Colors and Cosmetics Technology|Colors and Cosmetics Technology|Colors and Cosmetics Technology|Colors and Cosmetics Technology|Colors and Cosmetics Technology|Colors and Cosmetics Technology|Colors and Cosmetics Technology|Colors and Cosmetics Technology|Colors and Cosmetics Technology|Colors and Cosmetics Technology|Colors and Cosmetics Technology|Colors and Cosmetics Technology|Colors and Cosmetics Technology|Colors and Cosmetics Technology|Colors and Cosmetics Technology|Colors and Cosmetics Technology|Colors and Cosmetics Technology|Colors and Cosmetics Technology|Colors and Cosmetics Technology|Colors and Cosmetics Technology|Colors and Cosmetics Technology|Colors and Cosmetics Technology|Colors and Cosmetics Technology|Colors and Cosmetics Technology|Colors and Cosmetics Technology|Colors and Cosmetics Technology|Colors and Cosmetics Technology|Colors and Cosmetics Technology|Colors and Cosmetics Technology|Colors and Cosmetics Technology|Colors and Cosmetics Technology|Colors and Cosmetics Technology|Colors and Cosmetics Technology|Colors and Cosmetics Technology|Colors and Cosmetics Technology|Colors and Cosmetics Technology|Colors and Cosmetics Technology|Colors and Cosmetics Technology|Colors and Cosmetics Technology|Colors and Cosmetics Technology|Colors and Cosmetics Technology|Colors and Cosmetics Technology|Colors and Cosmetics Technology|Colors and Cosmetics Technology|Colors and Cosmetics Technology|Colors and Cosmetics Technology|Colors and Cosmetics Technology|Colors and Cosmetics Technology|Drug Quality Assurance|Unapproved and Misbranded Drugs|Drug Quality Assurance|Unapproved and Misbranded Drugs|Drug Quality Assurance|Unapproved and Misbranded Drugs|Drug Quality Assurance|Unapproved and Misbranded Drugs|Drug Quality Assurance|Unapproved and Misbranded Drugs|Drug Quality Assurance|Unapproved and Misbranded Drugs|Drug Quality Assurance|Unapproved and Misbranded Drugs|Drug Quality Assurance|Unapproved and Misbranded Drugs|Drug Quality Assurance|Unapproved and Misbranded Drugs|Drug Quality Assurance|Unapproved and Misbranded Drugs|Drug Quality Assurance|Unapproved and Misbranded Drugs|Drug Quality Assurance|Unapproved and Misbranded Drugs|Drug Quality Assurance|Unapproved and Misbranded Drugs|Drug Quality Assurance|Unapproved and Misbranded Drugs|Drug Quality Assurance|Unapproved and Misbranded Drugs|Drug Quality Assurance|Unapproved and Misbranded Drugs|Drug Quality Assurance|Unapproved and Misbranded Drugs|Drug Quality Assurance|Unapproved and Misbranded Drugs|Drug Quality Assurance|Unapproved and Misbranded Drugs|Drug Quality Assurance|Unapproved and Misbranded Drugs|Drug Quality Assurance|Unapproved and Misbranded Drugs|Drug Quality Assurance|Unapproved and Misbranded Drugs|Drug Quality Assurance|Unapproved and Misbranded Drugs|Drug Quality Assurance|Unapproved and Misbranded Drugs|Drug Quality Assurance|Unapproved and Misbranded Drugs|Drug Quality Assurance|Unapproved and Misbranded Drugs|Drug Quality Assurance|Unapproved and Misbranded Drugs|Drug Quality Assurance|Unapproved and Misbranded Drugs|Drug Quality Assurance|Unapproved and Misbranded Drugs|Drug Quality Assurance|Unapproved and Misbranded Drugs|Drug Quality Assurance|Unapproved and Misbranded Drugs|Drug Quality Assurance|Unapproved and Misbranded Drugs|Drug Quality Assurance|Unapproved and Misbranded Drugs|Drug Quality Assurance|Unapproved and Misbranded Drugs|Drug Quality Assurance|Unapproved and Misbranded Drugs|Drug Quality Assurance|Unapproved and Misbranded Drugs|Drug Quality Assurance|Unapproved and Misbranded Drugs|Drug Quality Assurance|Unapproved and Misbranded Drugs|Drug Quality Assurance|Unapproved and Misbranded Drugs|Drug Quality Assurance|Unapproved and Misbranded Drugs|Drug Quality Assurance|Unapproved and Misbranded Drugs|Drug Quality Assurance|Unapproved and Misbranded Drugs|Drug Quality Assurance|Unapproved and Misbranded Drugs|Drug Quality Assurance|Unapproved and Misbranded Drugs|Drug Quality Assurance|Unapproved and Misbranded Drugs|Drug Quality Assurance|Unapproved and Misbranded Drugs|Drug Quality Assurance|Unapproved and Misbranded Drugs|Drug Quality Assurance|Unapproved and Misbranded Drugs|Drug Quality Assurance|Unapproved and Misbranded Drugs|Drug Quality Assurance|Unapproved and Misbranded Drugs|Drug Quality Assurance|Unapproved and Misbranded Drugs|Drug Quality Assurance|Unapproved and Misbranded Drugs|Drug Quality Assurance|Unapproved and Misbranded Drugs|Drug Quality Assurance|Unapproved and Misbranded Drugs|Drug Quality Assurance|Unapproved and Misbranded Drugs|Drug Quality Assurance|Unapproved and Misbranded Drugs|Drug Quality Assurance|Unapproved and Misbranded Drugs|Drug Quality Assurance|Unapproved and Misbranded Drugs|Drug Quality Assurance|Unapproved and Misbranded Drugs|Drug Quality Assurance|Unapproved and Misbranded Drugs|Drug Quality Assurance|Unapproved and Misbranded Drugs|Drug Quality Assurance|Unapproved and Misbranded Drugs|Drug Quality Assurance|Unapproved and Misbranded Drugs|Drug Quality Assurance|Unapproved and Misbranded Drugs|Drug Quality Assurance|Unapproved and Misbranded Drugs|Drug Quality Assurance|Unapproved and Misbranded Drugs|Drug Quality Assurance|Unapproved and Misbranded Drugs|Drug Quality Assurance|Unapproved and Misbranded Drugs|Drug Quality Assurance|Unapproved and Misbranded Drugs|Drug Quality Assurance|Unapproved and Misbranded Drugs|Drug Quality Assurance|Unapproved and Misbranded Drugs |
| Product type | Drugs, Food/Cosmetics |
At a glance
- 1–9 Citations
- 1–9 Posted citations
- No Warning letter followed
- Yes Form FDA 483 issued
- No Establishment inspection report (EIR) exists
- 10–99 Inspections at this FEI
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About FDA inspections
FDA inspections are classified as No Action Indicated (NAI), Voluntary Action Indicated (VAI) or Official Action Indicated (OAI). Inspections of individual clinical investigators are not published here.
Source: U.S. Food and Drug Administration (FDA), inspection classification data